NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals has amended its two RNAi collaboration agreements with Merck and consolidated them into a single collaboration, Alnylam said today.
 
The amendments focus on the nine new therapeutic targets that Merck will name at a later date. These new programs are in addition to the existing collaboration on NOGO pathway for spinal cord injury treatments.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.